Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 7)
Volume 1
Issue 7

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Related Content